A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.
- Who can join
- Adults 45 to 75, have type 2 diabetes, BMI 30+.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The study runs about 11 months.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Type 2 Diabetes. Also studied in: BMI Greater Than 30.
Full scientific study title: Imaging in Semaglutide Study.
Who can join
Adults 45 to 75, have type 2 diabetes, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Gender: men and women
- Ethnicity: all ethnic groups
- Age between 45 and 75 years
- BMI ≥ 30 kg/m2 and BMI \< 45 kg/m2
- Diagnosis of Type 2 Diabetes (T2D) with HbA1c levels between 7% and 10.5%.
Key exclusion criteria
- Previous intolerance or allergy to any semaglutide-based therapy.
- History of prior intolerance to any GLP-1RA or GIP/GLP-1RA.
- Unwillingness or uncertainty to commit to the duration of the study.
- Contraindication to MRI (e.g. claustrophobia, implanted devices including cardiac pacemaker and cardioverter-defibrillators), circumference of largest calf \> 17 inch/43 cm (max size to fit into the MR coil).
- History of myocardial infarction or coronary revascularization (percutaneous intervention or coronary artery bypass) within 30 days prior to screening.
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
Ohio1 site
- Cleveland ClinicCleveland, Ohio
Timeline
Scheduled start: July 15, 2026. Expected completion: June 1, 2027. Last updated on ClinicalTrials.gov: July 10, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
